Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Studies in Health Technology and Informatics|June 21, 2011
Affective reactions to visually masked stimuli within a virtual environmentJason Drummond, Nadia Berthouze, Anthony SteedIEEE Transactions on Visualization and Computer Graphics|January 19, 2016
An 'In the Wild' Experiment on Presence and Embodiment using Consumer Virtual Reality EquipmentAnthony Steed, Sebastian Frlston, María Murcia López, et al.Bioorganic & Medicinal Chemistry Letters|April 30, 2013
Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug designXiaojing Wang, Steven Magnuson, Rich Pastor, et al.Journal of Medicinal Chemistry|May 18, 2012
Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modelingHuifen Chen, Bryan K Chan, Jason Drummond, et al.Bioorganic & Medicinal Chemistry Letters|December 8, 2018
Discovery of potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitors possessing a key intramolecular hydrogen bond - Part 2Daniel G M Shore, Zachary K Sweeney, Alan Beresford, et al.Journal of Medicinal Chemistry|November 23, 2017
Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico TechniquesPaola Di Lello, Richard Pastor, Jeremy M Murray, et al.Journal of Medicinal Chemistry|April 27, 2017
Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized BioavailabilityXiaojing Wang, Aleksandr Kolesnikov, Suzanne Tay, et al.Journal of Medicinal Chemistry|May 1, 2009
A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora BIgnacio Aliagas-Martin, Dan Burdick, Laura Corson, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 InhibitorBryan K Chan, Anthony A Estrada, Huifen Chen, et al.Journal of Medicinal Chemistry|July 18, 2008
A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailabilityThomas E Rawson, Matthias Rüth, Elizabeth Blackwood, et al.Pageof 2